autoimmune diseases

Displaying 9 studies

  • Biomarkers in Autoimmune and Inflammatory Diseases Rochester, MN

    The purpose of this study is to identify biomarkers in people with autoimmune or inflammatory disease and in healthy people. We will use these biomarkers to develop tests that will help us better understand the same biomarkers in the blood of people who have autoimmune and inflammatory diseases.

  • Studies of the Pathogenesis of Chronic Inflammatory Rheumatic Diseases Rochester, MN

    This study is being done to learn more about diseases with chronic and harmful inflammation. This study will look at what causes these diseases;  whether these diseases are inherited (genetic) or acquired (not genetic or inherited); and what are the signs, symptoms, or tests that can be used to predict how a patient will respond to therapy or which therapy may be the best one to use.

  • A Study to Evaluate the Long-Term Safety and Effectiveness of Caplacizumab for Patients who Completed Study ALX0681-C301 Rochester, MN

    The purpose of this study is to evaluate the long-term and repeated use safety and effectiveness of caplacizumab in patients who completed previous study ALX0681-C301.

  • A Registry for Data and Biospecimen of Cancer and Autoimmune Diseases Scottsdale/Phoenix, AZ; Rochester, MN

    The purpose of this study is to establish a repository consisting of clinical information, radiological data, serum, peripheral blood lymphocytes, plasma, cerebrospinal fluid (CSF), DNA and tissue specimens collected prospectively from participants with cancer and autoimmune diseases.

  • Ixekizumab in the Treatment of Bullous Pemphigoid Scottsdale/Phoenix, AZ

    Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the effect of Ixekizumab on BP patients.

  • Autoimmunity in the Pathogenesis of AF Rochester, MN

    This research study is being done to find out whether autoimmune mechanisms are associated with the development of atrial fibrillation.

  • A Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions (IMISC) Rochester, MN

    The purpose of this study is to create a research registry of patients with Immune-Mediated Inflammatory Skin Conditions (IMISC) within academic and community, real-world practices in order to assess the safety and effectiveness of current and future therapies.

  • Thyroid Autoimmunity Biobank Rochester, MN

    The purpose of this study is:

    1. To create a biospecimen and data resource of autoimmune thyroid disease patients and a control group of healthy volunteers for use in future research studies.Subjects will include:
      1. All newly diagnosed cases of autoimmune thyroid disease entities (Hashimoto’s thyroiditis, Graves’ disease, subacute thyroiditis, painless/lymphocytic/post-partum thyroiditis, Graves’ orbitopathy and Pretibial myxedema) seen at Mayo Clinic Rochester within 12-18 months of diagnosis.
    2. To utilize the cultured orbital fibroblasts for analyzing the role of IGF1r in GO pathophysiology and the potential role PAPP-A can play in that cascade, based on Dr. Conover’s research in the field.
    3. Development of improved ...

  • Dissecting the Genetic Environment Contributions of Autoimmune Liver Disease Rochester, MN

    The overall objective of this proposal is to conduct a systematic approach to dissect both genetic underpinnings and non-genetic factors in the development of adult autoimmune liver diseases including autoimmune hepatitis (AIH), overlap AIH with Primary Biliary Cirrhosis (AIH-PBC), overlap AIH with Primary Sclerosing Cholangitis (AIH-PSC), and drug-induced autoimmune-like hepatitis (DIAIH).

.

Mayo Clinic Footer